ArticleDiscover nano2026
Nanoencapsulation and antimicrobial activities of Commiphora swynnertonii resin against multidrug-resistant Staphylococcus aureus strains from mastitis cow patients.
Article in Discover nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Bovine mastitis is an inflammatory disease of the mammary gland, largely caused by microbial infections and commonly managed through intramammary administration of antibiotics. However, the extensive and recurrent use of antibiotics has led to the emergence and spread of antibiotic-resistant pathogens, particularly multidrug-resistant (MDR) Staphylococcus aureus, posing significant veterinary and public health challenges. Herein, we investigated the potential of Commiphora swynnertonii resin-loaded nanoparticles as an antibiotic alternative. This study aimed to identify an effective nanocarrier platform for antimicrobial delivery of C. swynnertonii resin. To achieve this, different types of nanocarriers were explored: liposomes, alginate-based nanoparticles, chitosan-based nanoparticles (ChN), solid lipid nanoparticles (SLN), and nanostructured lipid carriers (NLC), each with or without hyaluronic acid-stearylamine conjugate (HAC). Antimicrobial activity was assessed against 13 MDR S. aureus strains isolated from mastitis cow patients. Based on minimum inhibitory concentrations (MIC) and minimum bactericidal concentrations (MBC) assays, the tested nanocarriers were ranked in ascending order of antimicrobial coverage as follows: liposomes (0% inhibitory and 0% bactericidal), ChN (15.4% inhibitory and 0% bactericidal), NLC (23% inhibitory and 7.6% bactericidal), SLN (69% inhibitory and 46.2% bactericidal), and alginate nanoparticles (100% inhibitory and 53% bactericidal). HAC-containing alginate nanoparticles achieved the strongest activity, with MIC 26-417 µg/ mL and MBC 35-417 µg/mL, followed by HAC-containing SLN with MIC 17-417 µg/mL and MBC 278-417 µg/mL. These findings highlight the potential of alginate-HAC nanoparticles as a promising platform for delivering C. swynnertonii resin constituents, offering a novel strategy to combat MDR mastitis pathogens through plant-based nanotherapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.